1. Alberti KG, Eckel RH, Grundy SM, et al; International Diabetes
Federation Task Force on Epidemiology and Prevention; Hational
Heart, Lung, and Blood Institute; American Heart Association;
World Heart Federation; International Atherosclerosis Society;
International Association for the Study of Obesity. Harmonizing
the metabolic syndrome: a joint interim statement of the International
Diabetes Federation Task Force on Epidemiology and Prevention;
National Heart, Lung, and Blood Institute; American Heart
Association; World Heart Federation; International Atherosclerosis
Society; and International Association for the Study of Obesity.
Circulation. 2009;120:1640–1645.
2. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA;
American Heart Association; National Heart, Lung, and Blood
Institute; American Diabetes Association. Clinical management of
metabolic syndrome: report of the American Heart Association/
National Heart, Lung, and Blood Institute/American Diabetes
Association conference on scientific issues related to management.
Circulation. 2004;109:551–556.
3. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome.
Lancet. 2005;365:1415–1428.
4. Hotamisligil GS. Inflammation and metabolic disorders. Nature.
2006;444:860–867.
Tomooka S, et al.
5. Stoll LL, Denning GM, Weintraub NL. Potential role of endotoxin as
a proinflammatory mediator of atherosclerosis. Arterioscler Thromb
Vasc Biol. 2004;24:2227–2236.
6. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia
initiates obesity and insulin resistance. Diabetes. 2007;56:1761–
1772.
7. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota
control metabolic endotoxemia-induced inflammation in high-fat
diet–induced obesity and diabetes in mice. Diabetes. 2008;57:1470–
1481.
8. Fei N, Zhao L. An opportunistic pathogen isolated from the gut of an
obese human causes obesity in germfree mice. ISME J. 2013;7:880–
884.
9. Mehta NN, McGillicuddy FC, Anderson PD, et al. Experimental
endotoxemia induces adipose inflammation and insulin resistance in
humans. Diabetes. 2010;59:172–181.
10. Grube BJ, Cochane CG, Ye RD, et al. Lipopolysaccharide binding
protein expression in primary human hepatocytes and HepG2
hepatoma cells. J Biol Chem. 1994;269:8477–8482.
11. Gonzalez-Quintela A, Alonso M, Campos J, Vizcaino L, Loidi L,
Gude F. Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of
obesity. PLoS One. 2013;8:e54600.
12. Sun L, Yu Z, Ye X, et al. A marker of endotoxemia is associated
with obesity and related metabolic disorders in apparently healthy
Chinese. Diabetes Care. 2010;33:1925–1932.
13. Gavaldà-Navarro A, Moreno-Navarrete JM, Quesada-López T, et al.
Lipopolysaccharide-binding protein is a negative regulator of adipose
tissue browning in mice and humans. Diabetologia. 2016;59:2208–
2218.
14. Schumann RR. Old and new findings on lipopolysaccharide-binding
protein: a soluble pattern-recognition molecule. Biochem Soc Trans.
2011;39:989–993.
15. Vaure C, Liu Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front Immunol.
2014;5:316.
16. Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding
protein plasma levels and liver TNF-alpha gene expression in obese
patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 2007;17:1374–
1380.
17. Hudgins LC, Parker TS, Levine DM, et al. A single intravenous dose
of endotoxin rapidly alters serum lipoproteins and lipid transfer
proteins in normal volunteers. J Lipid Res. 2003;44:1489–1498.
18. Novitsky TJ. Limitations of the Limulus amebocyte lysate test in
demonstrating circulating lipopolysaccharides. Ann N Y Acad Sci.
1998;851:416–421.
19. Citronberg JS, Wilkens LR, Lim U, et al. Reliability of plasma
lipopolysaccharide-binding protein (LBP) from repeated measures in
healthy adults. Cancer Causes Control. 2016;27:1163–1166.
20. Awoyemi A, Trøseid M, Arnesen H, Solheim S, Seljeflot I. Markers
of metabolic endotoxemia as related to metabolic syndrome in an
elderly male population at high cardiovascular risk: a cross-sectional
study. Diabetol Metab Syndr. 2018;10:59.
21. Lim PS, Chang YK, Wu TK. Serum lipopolysaccharide-binding
protein is associated with chronic inflammation and metabolic
syndrome in hemodialysis patients. Blood Purif. 2019;47:28–36.
22. Liu X, Lu L, Yao P, et al. Lipopolysaccharide binding protein,
obesity status and incidence of metabolic syndrome: a prospective
study among middle-aged and older Chinese. Diabetologia. 2014;
57:1834–1841.
23. Ninomiya T. Japanese legacy cohort studies: the Hisayama Study.
J Epidemiol. 2018;28:444–451.
24. Asada M, Oishi E, Sakata S, et al. Serum lipopolysaccharide-binding
protein levels and the incidence of cardiovascular disease in a general
Japanese population: the Hisayama Study. J Am Heart Assoc. 2019;8:
e013628.
25. Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. Definition and the diagnostic standard for metabolic syndrome. Nihon Naika Gakkai Zasshi. 2005;94:794–809 [in Japanese].
26. Doi Y, Ninomiya T, Hata J, et al. Proposed criteria for metabolic
syndrome in Japanese based on prospective evidence: the Hisayama
Study. Stroke. 2009;40:1187–1194.
27. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new worldwide definition. A consensus statement from the International
Diabetes Federation. Diabet Med. 2006;23:469–480.
28. Balkau B, Charles MA. Comment on the provisional report from
the WHO consultation. European Group for the Study of Insulin
Resistance (EGIR). Diabet Med. 1999;16:442–443.
29. Paul DA. Change scores as dependent variables in regression
analysis. Sociol Methodol. 1990;20:93–114.
30. Ghanim H, Abuaysheh S, Sia CL, et al. Increase in plasma
endotoxin concentrations and the expression of Toll-like receptors
and suppressor of cytokine signaling-3 in mononuclear cells after a
high-fat, high-carbohydrate meal: implications for insulin resistance.
Diabetes Care. 2009;32:2281–2287.
31. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted
syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care.
1991;14:173–194.
32. Vreugdenhil AC, Dentener MA, Snoek AM, Greve JW, Buurman
WA. Lipopolysaccharide binding protein and serum amyloid A
secretion by human intestinal epithelial cells during the acute phase
response. J Immunol. 1999;163:2792–2798.
33. Moreno-Navarrete JM, Escoté X, Ortega F, et al. A role for
adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. Diabetologia. 2013;56:2524–2537.
34. Trøseid M, Nestvold TK, Rudi K, Thoresen H, Nielsen EW,
Lappegård KT. Plasma lipopolysaccharide is closely associated with
glycemic control and abdominal obesity: evidence from bariatric
surgery. Diabetes Care. 2013;36:3627–3632.
35. Moreno-Navarrete JM, Ortega F, Serino M, et al. Circulating
lipopolysaccharide-binding protein (LBP) as a marker of obesityrelated insulin resistance. Int J Obes (Lond). 2012;36:1442–1449.
36. Laugerette F, Alligier M, Bastard JP, et al. Overfeeding increases
postprandial endotoxemia in men: inflammatory outcome may
depend on LPS transporters LBP and sCD14. Mol Nutr Food Res.
2014;58:1513–1518.
37. Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME.
Impact of the gut microbiota on inflammation, obesity, and metabolic
disease. Genome Med. 2016;8:42.
J Epidemiol 2024
...
論文の公開元へ
